Naito Y, Aburatani H, Amano T et al (2021) Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol 26(2):233–283

Article  PubMed  Google Scholar 

Naito Y, Mishima S, Akagi K et al (2020) Japan Society of clinical oncology/Japanese Society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol 25(3):403–417

Article  PubMed  PubMed Central  Google Scholar 

Sunami K, Bando H, Yatabe Y et al (2021) Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. Cancer Sci 112(9):3911–3917

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yatabe Y, Sunami K, Goto K et al (2020) Multiplex gene-panel testing for lung cancer patients. Pathol Int 70(12):921–931

Article  PubMed  Google Scholar 

Sunami K, Hatanaka Y, Koyama T (2020) Practical guide to cancer genome medicine gene panel testing. Igaku-Shoin Press (in Japanese)

Yabana N (2018) Trends in regulation and evaluation of companion diagnostics. Proc Jpn Soc Pathol 107(1):199 (in Japanese)

Google Scholar 

Hatanaka Y, Kuwata T, Morii E et al (2021) The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine. Pathol Int 71(11):725–740

Article  PubMed  PubMed Central  Google Scholar 

Morii E, Hatanaka Y, Motoi N et al (2023) Guidelines for handling of cytological specimens in cancer genomic medicine. Pathobiology 8:1–23

Google Scholar 

Yanagihara R (2018) Regulatory perspectives on NGS-based IVDs. Japanese Society of medical oncology annual meeting. Proc Jpn Soc Med Oncol 16(1):91 (in Japanese)

Google Scholar 

Davies KD, Aisner DL (2019) Wake up and smell the fusions: single-modality molecular testing misses drivers. Clin Cancer Res 25(15):4586–4588

Article  CAS  PubMed  Google Scholar 

Marchiò C, Scaltriti M, Ladanyi M et al (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30(9):1417–1427

Article  PubMed  Google Scholar 

Ministry of Health, Labour and Welfare Meeting Material (2022) Designation requirements for core hospitals and cooperative hospitals for cancer genomic medicine" https://www.mhlw.go.jp/content/10901000/000962791.pdf (in Japanese)

Kohno T, Kato M, Kohsaka S et al (2022) C-CAT: the national datacenter for cancer genomic medicine in Japan. Cancer Discov 12(11):2509–2515

Article  PubMed  PubMed Central  Google Scholar 

Ministry of Health, Labour and Welfare Director Notification (2016) Handling of the manufacture and sale of DNA sequencers, etc. for use in genetic testing systems https://www.pmda.go.jp/files/000213137.pdf (in Japanese)

Mano H (2020) Cancer genomic medicine in Japan. Proc Jpn Acad Ser B Phys Biol Sci 96:316–321

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brunet JF, Denizot F, Luciani MF et al (1987) A new member of the immunoglobulin superfamily–CTLA-4. Nature 328:267–270

Article  CAS  PubMed  Google Scholar 

Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736

Article  CAS  PubMed  Google Scholar 

Hoos A, Ibrahim R, Korman A et al (2010) Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37:533–546

Article  CAS  PubMed  Google Scholar 

Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17:6958–6962

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riaz N, Havel JJ, Makarov V et al (2017) Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171(934–949):e16

Google Scholar 

Tanaka A, Sakaguchi S (2017) Regulatory T cells in cancer immunotherapy. Cell Res 27:109–118

Article  CAS  PubMed  Google Scholar 

Arce Vargas F, Furness AJS, Litchfield K et al (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33(649–663):e4

Google Scholar 

Hui E, Cheung J, Zhu J et al (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355:1428–1433

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumagai S, Togashi Y, Kamada T et al (2020) The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21:1346–1358

Article  CAS  PubMed  Google Scholar 

Francisco LM, Salinas VH, Brown KE et al (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015–3029

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207–212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butte MJ, Keir ME, Phamduy TB et al (2007) Programmed death-1 ligand 1 interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses. Immunity 27:111–122

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park JJ, Omiya R, Matsumura Y et al (2010) B7–H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116:1291–1298

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Taube JM, Anders RA et al (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257

CAS  PubMed  Google Scholar 

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dudley JC, Lin MT, Le DT et al (2016) Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res 22:813–820

Article  CAS  PubMed  Google Scholar 

Japan Society of Clinical Oncology, Japanese Society of Medical Oncology (2019) Guidelines for cross-organ genomic practice in adult and pediatric advanced solid tumors, 2nd edn (in Japanese). Tokyo Japan

Mishima S, Taniguchi H, Akagi K, et al (2020) Japan society of clinical oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. Int J Clin Oncol 25: 217–239

Yoshino T, Pentheroudakis G, Mishima S et al (2020) JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 31:861–872

Article  CAS  PubMed  Google Scholar 

Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282

Article  CAS  PubMed  Google Scholar 

Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21:531–540

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bebb DG, Banerji S, Blais N et al (2021) Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults. Curr Oncol 28:523–548

Article  PubMed  PubMed Central  Google Scholar 

Demetri GD, Antonescu CR, Bjerkehagen B et al (2020) Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol 31:1506–1517

Article  CAS  PubMed  Google Scholar 

Marchiò C, Scaltriti M, Ladanyi M et al (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30:1417–1427

Article  PubMed  Google Scholar 

Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532

Article  CAS  PubMed  Google Scholar